Targeting MAGE-C1/CT7 expression increases cell sensitivity to the proteasome inhibitor bortezomib in multiple myeloma cell lines

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  de Carvalho, Fabricio ^a   Costa, Erico T ^b   Camargo, Anamaria A ^b   Gregorio, Juliana C ^b   Masotti, Cibele ^b   Andrade, Valeria C C ^a   Strauss, Bryan E ^c   Caballero, Otavia L ^d   Atanackovic, Djordje ^e   Colleoni, Gisele W B ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CANCER TESTIS ANTIGEN; MAGE C1 ANTIGEN; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; MAGEC1 PROTEIN, HUMAN; PROTEASOME; PROTEINASE INHIBITOR; PYRAZINE DERIVATIVE; SMALL INTERFERING RNA; TUMOR ANTIGEN; TUMOR PROTEIN;

ANTIGEN EXPRESSION; ARTICLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS; DOWN REGULATION; DRUG MECHANISM; DRUG TARGETING; GENE SILENCING; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; APOPTOSIS; CANCER INVASION; CELL DIVISION; DRUG ANTAGONISM; DRUG EFFECT; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; TUMOR CELL LINE;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; APOPTOSIS; BORONIC ACIDS; CELL DIVISION; CELL LINE, TUMOR; CELL PROLIFERATION; G2 PHASE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MULTIPLE MYELOMA; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; RNA, SMALL INTERFERING;

EID: 81155134249     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027707     Document Type: Article

References (53)

1. Ludwig H, Beksac M, Bladé J, Boccadoro M, Cavenagh J, et al. (2010) Current multiple myeloma treatment strategies with novel agents: a european perspective. Oncologist 15: 6-25.
2. Nadav L, Katz BZ, Baron S, Cohen N, Naparstek E, et al. (2006) The generation and regulation of functional diversity of malignant plasma cell. Cancer Res 66: 8608-8616.
3. Noborio-Hatano K, Kikuchi J, Takatoku M, Shimizu R, Wada T, et al. (2009) Bortezomib overcomes cell adhesion-mediated drug resistance through downregulation of VLA-4 expression in multiple myeloma. Oncogene 28: 231-242.
4. Shain KH, Yarde DN, Meads MB, Huang M, Jove R, et al. (2009) β1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Res 69: 1009-1015.
5. Broyl A, Hose D, Lokhorst H, Knegt Y, Peeters J, et al. (2010) Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood 116: 2543-2553.
6. Ludwig H, (2005) Advances in biology and treatment of multiple myeloma. Ann Oncol 16: ii106-ii112.
7. Richardson PG, Mitsiades C, Schlossman R, Munshi N, Anderson K, (2007) New drugs for myeloma. Oncologist 12: 664-689.
8. White DJ, Paul N, Macdonald DA, Meyer RM, Shepherd LE, (2007) Addition of lenalidomide to melphalan in the treatment of newly diagnosed multiple myeloma: the national cancer institute of Canada clinical trials group MY.11 trial. Curr Oncol 14: 61-65.
9. Kyle RA, Rajkumar V, (2008) Multiple myeloma. Blood 111: 2962-2972.
10. Jungbluth AA, Ely S, Diliberto M, Niesvizky R, Williamson B, et al. (2005) The cancer-testis antigens CT7 (MAGEC1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood 106: 167-174.
11. Condomines M, Hose D, Raynaud P, Hundemer M, Vos JD, et al. (2007) Cancer/testis genes in multiple myeloma: expression patterns and prognosis value determined by microarray analysis. J Immunol 178: 3307-3315.
12. Hoffmann O, Caballero OL, Stevenson BJ, Chen YT, Cohen T, et al. (2008) Genome-wide analysis of cancer/testis gene expression. Proc Natl Acad Sci USA 105: 20422-20427.
13. Tinguely M, Jenni B, Knights A, Lopes B, Korol D, et al. (2008) MAGE-C1/CT-7 expression in plasma cell myeloma: sub-cellular localization impacts on clinical outcome. Cancer Sci 99: 720-725.
14. Lendvai N, Gnjatic S, Ritter E, Mangone M, Austin W, et al. (2010) Cellular immune responses against CT7 (MAGE-C1) and humoral responses against other cancer-testis antigens in multiple myeloma patients. Cancer Immun 10: 4.
15. Cho HJ, Caballero OL, Gnjatic S, Andrade VCC, Colleoni GW, et al. (2006) Physical interaction of two cancer-testis antigens, MAGE-C1 (CT7) and NY-ESO-1 (CT6). Cancer Immun 6: 12.
16. Peng J, Chen H, Mou D, Cao J, Cong X, et al. (2005) Expression of cancer/testis (CT) antigens in chinese hepatocellular carcinoma and its correlation with clinical parameters. Cancer Lett 219: 223-232.
17. Caballero OL, Zhao Q, Rimoldi D, Stevenson BJ, Svobodová S, et al. (2010) Frequent MAGE mutations in human melanoma. PLoS One 5: e12773.
18. Curioni-Fontecedro A, Nuber N, Mihic-Probst D, Seifert B, Soldini D, et al. (2011) Expression of MAGE-C1/CT7 and MAGE-C2/CT10 predicts lymph node metastasis in melanoma patients. PLoS One 6: e21418.
19. Costa FF, Blanc KL, Brodin B, (2007) Concise review: cancer/testis antigens, stem cells, and cancer. Stem Cells 25: 707-711.
20. Scanlan MJ, Simpson AJG, Old LJ, (2004) The cancer/testis genes: review, standardization, and commentary. Cancer Immun 4: 1.
21. Atanackovic D, Luetkens T, Hildebrandt Y, Arfsten J, Bartels K, et al. (2009) Longitudinal analysis and prognostic effect of cancer-testis antigen expression in multiple myeloma. Clin Cancer Res 15: 1343-1352.
22. Stevenson BJ, Iseli C, Panji S, Zahn-Zabal M, Hide W, et al. (2007) Rapid evolution of cancer/testis gene on the X chromosome. BMC Genomics 8: 129.
23. Spatz A, Borg C, Feunteun J, (2004) X-chromosome genetics and human cancer. Nat Rev Cancer 4: 617-629.
24. Caballero OL, Chen YT, (2009) Cancer/testis (CT) antigens: potential targets for immunotherapy. Cancer Sci 100: 2014-2021.
25. Lucas S, Smet CD, Arden KC, Viars CS, Lethé B, et al. (1998) Identification of a new MAGE gene with tumor-specific expression by representational difference analysis. Cancer Res 58: 743-752.
26. Chen YT, Güre AO, Tsang S, Stockert E, Jäger E, et al. (1998) Identification of multiple cancer/testis antigens by allogeneic antibody screening of a melanoma cell line library. Proc Natl Acad Sci USA 95: 6919-6923.
27. Krüger S, Ola V, Feller A, Fischer D, Friedrich M, (2007) Expression of cancer-testis antigen CT7 (MAGE-C1) in breast cancer: an immunohistochemical study with emphasis on prognostic utility. Pathol Oncol Res 13: 91-96.
28. Huff CA, Karp JE, (2005) Should MAGE be the rage in myeloma? Blood 106: 5.
29. Andrade VCC, Vettore AL, Felix RS, Almeida MSS, Carvalho F, et al. (2008) Prognostic impact of cancer testis antigens expression in advanced stage multiple myeloma patients. Cancer Immun 8: 2.
30. Song L, Li Y, Shen B, (2002) Protein kinase ERK contributes to differential responsiveness of human myeloma cell lines to IFNα. Cancer Cell Int 2: 9.
31. Atanackovic D, Hildebrandt Y, Jadczak A, Cao Y, Luetkens T, et al. (2010) Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 are central survival factors for multiple myeloma cells. Haematologica 95: 785-793.
32. Yang B, O'Herrin S, Wu J, Reagan-Shaw S, Ma Y, et al. (2007) Select cancer testes antigens of the MAGE-A,-B, and-C families are expressed in mast cell lines and promote cell viability in vitro and in vivo. J Invest Dermatol 127: 267-275.
33. Duan Z, Duan Y, Lamendola DE, Yusuf RZ, Naeem R, et al. (2003) Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines. Clin Cancer Res 9: 2778-2785.
34. Suzuki T, Yoshida K, Wada Y, Hamai Y, Sentani K, et al. (2007) Melanoma-associated antigen-A1 expression predicts resistance to docetaxel and paclitaxel in advanced and recurrent gastric cancer. Oncol Rep 18: 329-336.
35. Tamura D, Arao T, Tanaka K, Kaneda H, Matsumoto K, et al. (2010) Bortezomib potentially inhibits cellular growth of vascular endothelial cells through suppression of G2/M transition. Cancer Sci 101: 1403-1408.
36. Pei XY, Dai Y, Grant S, (2004) Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 10: 3839-3852.
37. Liu P, Xu B, Li J, Lu H, (2009) BAG3 gene silencing sensitizes leukemic cells to bortezomib-induced apoptosis. FEBS Lett 583: 401-406.
38. Leonard JP, Furman RR, Coleman M, (2006) Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma. Int J Cancer 119: 971-979.
39. Ling YH, Liebes L, Jiang JD, Holland JF, Elliott PJ, et al. (2003) Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines. Clin Cancer Res 9: 1145-1154.
40. Yang B, O'Herrin S, Wu J, Reagan-Shaw S, Ma Y, et al. (2007) MAGE-A, MAGE-B, and MAGE-C proteins forma complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positives cell lines. Cancer Res 67: 9954-9962.
41. Olsson L, Kaplan HS, (1980) Human-human hybridomas producing monoclonal antibodies of predefined antigenic specificity. Proc Natl Acad Sci USA 77: 5429-5431.
42. Matsuoka Y, Moore GE, Yagi Y, Pressman D, (1967) Production of free light chains of immunoglobulin by a hematopoietic cell line derived a patient with multiple myeloma. Proc Soc Exp Biol Med 125: 1246-1250.
43. Nilsson K, Bennich H, Johansson SGO, Pontén J, (1970) Established immunoglobulin producing myeloma (IgE) and lumphoblastoid (IgG) cell lines from an IgE myeloma patient. Clin Exp Immunol 7: 477-489.
44. Eton O, Scheinberg DA, Houghton AN, (1989) Establishment and characterization of two human myeloma cell lines secreting kappa light chains. Leukemia 3: 729-735.
45. Jungbluth AA, Chen YT, Busam KJ, Coplan K, Kolb D, et al. (2002) CT7 (MAGE-C1) antigen expression in normal and neoplastic tissues. Int J Cancer 99: 839-845.
46. Naviaux RK, Costanzi E, Haas M, Verma IM, (1996) The pCL vector system: rapid production of helper-free, high-titer, recombinant retroviruses. J Virol 70: 5701-5705.
47. Brummelkamp TR, Bernards R, Agami R, (2002) Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2: 243-247.
48. Bajgelman MC, Costanzi-Strauss E, Strauss BE, (2003) Exploration of critical parameters for transient retrovirus production. J Biotechnol 103: 97-106.
49. Graham FL, Smiley J, Russell WC, Nairn R, (1977) Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36: 59-74.
50. Costanzi-Strauss E, Strauss BE, Naviaux RK, Haas M, (1998) Restoration of growth arrest by p16INK4, p21WAF1, pRB, and p53 is depedent on the integrity of the endogenous cell-cycle control pathways in human glioblastoma cell lines. Exp Cell Res 238: 51-62.
51. Holt RU, Baykov V, Rø TB, Brabrand S, Waage A, et al. (2005) Human myeloma cell adhere to fibronectin in response to hepatocyte growth factor. Haematologica 90: 479-488.
52. Strait KA, Dabbas B, Hammond EH, Warnick T, Ilstrup SJ, et al. (2002) Cell cycle blockade and differentiation of ovarian cancer cells by the histone deacetylase inhibitor trichostatin A are associated with changes in p21, Rb, and Id proteins. Mol Cancer Ther 1: 1181-1190.
53. Alexopoulou AN, Leao M, Caballero OL, Da Silva L, Reid L, et al. (2010) Dissecting the transcriptional networks underlying breast cancer: NR4A1 reduces the migration of normal and breast cancer cell lines. Breast Cancer Res 12: R51.